Effect of S-Ibuprofen Gel on Pain in Acute Soft Tissue Contusions

November 4, 2026 updated by: Aponia Laboratories, Inc.

Randomized, Controlled, Multi-center Trial to Evaluate the Efficacy, Tolerability, and Safety of an S-Ibuprofen Gel vs. Placebo in the Local Symptomatic and Short-Term Treatment of Pain in Acute Contusions of the Soft Tissues Following Blunt Trauma

Phase 3 study designed to evaluated analgesic efficacy and safety of S-Ibuprofen Topical Gel 5%

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

The purpose of this randomized, double-blind study is to evaluate the efficacy and safety of S-Ibuprofen Topical Gel 5% in treatment of pain in acute contusions of the soft tissues following blunt trauma.

Study Type

Interventional

Enrollment (Estimated)

240

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bonn, Germany, 53113
        • Recruiting
        • Dr. med Jürgen Ulrich Schaale-Maas
        • Contact:
      • Bonn, Germany, 53121
        • Recruiting
        • Orthopädische Praxis-Ebert
        • Contact:
          • Eduart Ebert, Dr. med.
          • Phone Number: +49 173 7038059
          • Email: ebert.e@web.de
      • Gilching, Germany, 82205
        • Recruiting
        • Dr. Helmut Pabst
        • Contact:
    • Oregon
      • Bend, Oregon, United States, 97702
        • Recruiting
        • Northwest Foot Care - Amanda Westfall McCarty
        • Contact:
      • Bend, Oregon, United States, 97702
        • Recruiting
        • Northwest Foot Care - Bryan Wilhelm
        • Contact:
      • Bend, Oregon, United States, 97702
        • Recruiting
        • Northwest Foot Care - Hayden Bush
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Acute soft-tissue injury/contusion.
  2. Enrollment within 6 hours of the injury.
  3. Baseline NRS score for POM of injured location >5 score points on an 11-point NRS.
  4. Size of injury, as assessed by the investigator, ≥25 cm2 and ≤120 cm2
  5. Adult male or female patients aged ≥18 years.
  6. Having given written informed consent.
  7. Satisfactory health as determined by the investigator based on medical history and physical examination.

Exclusion Criteria:

  1. Significant concomitant injury in association with the acute injury; e.g., fracture, nerve injury, ligament disruption, tear of muscle or cartilage, or open wound.
  2. Excessively hairy skin at application site, cutting the hair in the injured site prior to gel application will qualify for inclusion.
  3. Current skin disorder or shaving hair at application site.
  4. History of excessive sweating/hyperhidrosis inclusive of application site.
  5. Treatment with topical or systemic NSAIDs or analgesics within 36 hours, opioids within 7 days, or corticosteroids within 60 days of inclusion in the study.
  6. Intake of long-acting NSAIDs or application of topical medication since the injury (rest-ice-compression-elevation [RICE] is allowed).
  7. Participation in a clinical study within 30 days before inclusion in the study or concomitantly.
  8. Positive drug or alcohol screen or evidence of drug or alcohol abuse in the opinion of the investigator.
  9. Pregnant or lactating or intending to become pregnant during the study.
  10. Individuals of reproductive potential who do not agree to use of an acceptable birth control method throughout the study, when engaging in any sexual activity that comes with a risk of pregnancy.
  11. History of any allergy or hypersensitivity (e.g., anaphylaxis, urticaria/hives, rhinitis, skin reaction, asthma, angioedema, or other allergic symptoms) to acetaminophen, ibuprofen, other NSAIDs, or to 1 of the excipients of the gel.
  12. History of severe cutaneous adverse reactions to any medication, such as Stevens-Johnson syndrome (SJS), erythema multiforme, toxic epidermal necrolysis (TEN), or acute generalized exanthematous pustulosis.
  13. Any ongoing condition that may interfere with the absorption, distribution, metabolism, or excretion of S-ibuprofen gel 5%.
  14. History of previous significant injury to the same extremity within 6 months.
  15. Patients with a disease affecting the same area, such as synovitis, rheumatoid arthritis, arthrosis, etc.
  16. Patients experiencing symptoms of an infectious disease including swelling of any joint of the affected area.
  17. Patients having an ongoing painful condition associated with the injury/contusion.
  18. Patients who had surgery of the affected area within 1 year of study entry.
  19. Patients with significant diseases (defined as a disease which, in the opinion of the investigator, may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study; including patients with a history of gastrointestinal bleeding, significant cardiovascular, liver, or renal disease).
  20. Patients with a blood coagulation disorder.
  21. Patients who use any impermissible medication (eg. systemic or topical NSAIDs, analgesics (other than paracetamol), opiods, corticosteroids (except for topical treatment of bronchial asthma, heparin, or psychotropic agents)
  22. Patients who participated in previous clinical studies of S-ibuprofen gel 5% and patients of the same household.
  23. Patients who are related to those persons involved directly or indirectly with the conduct of the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: S-Ibuprofen Topical Gel 5%

S-Ibuprofen Topical Gel 5% applied once per day to the affected injury site

Topical gel containing active ingredient S-ibuprofen

Placebo Comparator: Vehicle Topical Gel

Placebo Gel applied once per day to the affected injury site

Placebo gel matching the active comparator in conposition and appearance without the active ingredient

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluation of the efficacy of S-ibuprofen gel 5% applied once every 24 hours compared with placebo in patients with acute contusions of the soft tissues following blunt trauma
Time Frame: 0-24 hours

Change from baseline/pain intensity difference of numerical rating scale (NRS) scores for pain-on-movement at 24 hours. NRS scale 0-10, 0=no pain, 10=worst possible pain.

0-24 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Time to first perceptible pain relief based on direct questions to the patient and what they consider perceptible pain relief
Time Frame: From time 0 every 24 hours up to 7 days

Recorded as time in minutes. Optional use of NRS scale. NRS scale 0-10, 0=no pain, 10=worst possible pain.

From time 0 every 24 hours up to 7 days
Time to onset of meaningful pain relief based on direct questions to the patient and what they consider meaningful pain relief
Time Frame: From time 0 to end of study (day 7)

Recorded as time in minutes. Optional use of NRS scale. NRS scale 0-10, 0=no pain, 10=worst possible pain.

From time 0 to end of study (day 7)
Time gap between first perceptible pain relief and meaningful pain relief based on direct questions to the patient
Time Frame: From time 0 to end of study (day 7)

Calculated as a difference to reach perceptible vs meaningul pain relief.

From time 0 to end of study (day 7)
Change from baseline/pain intensity difference of numerical rating scale (NRS) scores for spontaneous pain-on-movement (sPOM) at 24 hours
Time Frame: At 24 hours

Recorded in patient diary based on NRS scores for sPOM at 24 hours. NRS scale 0-10, 0=no pain, 10=worst possible pain.

At 24 hours
Change from baseline for pain-at-rest (PAR) measured by numerical rating scale (NRS) at Visit 2, Visit 3, Visit 4, Visit 5, Visit 6
Time Frame: At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)

Based on NRS scores for PAR at 24 hours. NRS scale 0-10, 0=no pain, 10=worst possible pain.

At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
Change from baseline for pain-on-movement (POM) measured at Visit 3, Visit 4, Visit 5, and Visit 6
Time Frame: At Visit 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)

Based on NRS scores for POM. NRS scale 0-10, 0=no pain, 10=worst possible pain.

At Visit 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
Change from baseline for spontaneous pain-on-movement measured at 6 (±2), 8 (±2), 12 (±2), 16 (±2), 24 (±4), 36 (±4), 48 (±4), 60 (±4), 72 (±4), 84 (±4), 96 (±4), 120 (±4), 144 (±4), and 168 (±24) hours
Time Frame: 6 (±2), 8 (±2), 12 (±2), 16 (±2), 24 (±4), 36 (±4), 48 (±4), 60 (±4), 72 (±4), 84 (±4), 96 (±4), 120 (±4), 144 (±4), and 168 (±24) hours after initial treatment administration

When possible, recorded in patient diary. NRS scale 0-10, 0=no pain, 10=worst possible pain.

6 (±2), 8 (±2), 12 (±2), 16 (±2), 24 (±4), 36 (±4), 48 (±4), 60 (±4), 72 (±4), 84 (±4), 96 (±4), 120 (±4), 144 (±4), and 168 (±24) hours after initial treatment administration
Pain-on-movement at the injured site recorded on a numerical rating scale (NRS) scale in the presence of the investigator for the timepoints at Visit 2, Visit 3, Visit 4, Visit 5, and Visit 6
Time Frame: At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)

NRS scale 0-10, 0=no pain, 10=worst possible pain.

At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
Sum of pain intensity differences (SPIDs) for pain-on-movement at Visit 2, Visit 3, Visit 4, Visit 5, and Visit 6
Time Frame: At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)

NRS scale 0-10, 0=no pain, 10=worst possible pain.

At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
Baseline-adjusted area under the curve (AUC) for pain-on-movement at the injured site recorded on a numerical rating scale (NRS) in the presence of the investigator for the timepoints at Visit 2, Visit 3, Visit 4, Visit 5, and Visit 6
Time Frame: At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)

NRS scale 0-10, 0=no pain, 10=worst possible pain.

At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
Pain at rest measured by a numerical rating scale (NRS) at baseline at Visit 2, Visit 3, Visit 4, Visit 5, and Visit 6
Time Frame: At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)

NRS scale 0-10, 0=no pain, 10=worst possible pain.

At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), 5 (~96 hours) and 6 (~168 hours)
Time-specific pain intensity difference for spontaneous pain-on-movement at all time points
Time Frame: Time 0 to end of study (day 7)

Recorded in patient diary. Calculated from NRS scale data generated throughout the study. NRS scale 0-10, 0=no pain, 10=worst possible pain.

Time 0 to end of study (day 7)
Time-specific pain intensity difference for pain at rest at all time points
Time Frame: Time 0 to end of study (day 7)

Recorded in patient diary. Calculated from NRS scale data generated throughout the study.NRS scale 0-10, 0=no pain, 10=worst possible pain.

Time 0 to end of study (day 7)
Time-specific pain intensity difference for spontaneous pain on movement at all time points
Time Frame: Time 0 to end of study (day 7)

Recorded in patient diary. Calculated from NRS scale data generated throughout the study. NRS scale 0-10, 0=no pain, 10=worst possible pain.

Time 0 to end of study (day 7)
Time-specific pain intensity difference for pain at rest at all time points
Time Frame: Time 0 to end of study (day 7)

Recorded in patient diary. Calculated from NRS scale data generated throughout the study. NRS scale 0-10, 0=no pain, 10=worst possible pain.

Time 0 to end of study (day 7)
Time to complete pain relief (Score = 0 pain)
Time Frame: Time 0 to end of study (day 7)

NRS scale 0-10, 0=no pain, 10=worst possible pain.

Time 0 to end of study (day 7)
Time to complete resolution of pain-on-movement (Score = 0 pain)
Time Frame: Time 0 to end of study (day 7)

NRS scale 0-10, 0=no pain, 10=worst possible pain.

Time 0 to end of study (day 7)
Time to complete resolution of pain at rest (Score = 0 of pain)
Time Frame: Time 0 to end of study (day 7)

NRS scale 0-10, 0=no pain, 10=worst possible pain.

Time 0 to end of study (day 7)
Time to the first request of rescue medication within the first 24 hours
Time Frame: Time 0 to 24 hours

If applicable

Time 0 to 24 hours
Proportion of patients taking rescue medication per dosing interval and during the entire evaluation period
Time Frame: Time 0 to end of study (day 7)

If applicable

Time 0 to end of study (day 7)
Responder rate (defined as the number of patients achieving 50% reduction from baseline in the NRS score for pain-on-movement at 24 hours)
Time Frame: Time 0 to 24 hours

NRS scale 0-10, 0=no pain, 10=worst possible pain.

Time 0 to 24 hours
Global efficacy assessment by investigator (5 point scale) at Visit 2, Visit 3, Visit 4, and Visit 6
Time Frame: At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), and 6 (~168 hours)

5-point Likert scale. 0 = excellent, 4 = very poor

At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), and 6 (~168 hours)
Global efficacy assessments by patient (5 point scale) at Visit 2, Visit 3, Visit 4, and Visit 6
Time Frame: At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), and 6 (~168 hours)

5-point Likert scale. 0 = excellent, 4 = very poor

At Visit 2 (~24 hours), 3 (~48 hours), 4 (~72 hours), and 6 (~168 hours)
Overall dose of rescue medication
Time Frame: Time 0 to end of study (Day 7)

Rescue medication use will be assessed at every visit except Visit 1

Time 0 to end of study (Day 7)
Local tolerability at every visit except V1
Time Frame: Time 0 to end of study (day 7)

Examination for presence of erythema (0-3, 0 = none; 3 = severe), edema (0-3, 0 = none; 3 = severe), papiculation/vesiculation (0-3, 0 = none; 3 = severe), pruritus (NRS scale 0-10; 0 = no itch, 10 = worst possible itch), burning (NRS scale 0-10; 0 = no itch, 10 = worst possible itch)

Time 0 to end of study (day 7)
Blood pressure exam at V1 and V6
Time Frame: At Visit 1 (time 0) and 6 (168 hours)

Systolic/diastolic blood pressure

At Visit 1 (time 0) and 6 (168 hours)
Adverse events at every visit
Time Frame: Time 0 to end of study (day 7)
Time 0 to end of study (day 7)
Examination of pulse at V1 and V6
Time Frame: At Visit 1 (time 0) and 6 (168 hours)

Pulse measured as beats per minute

At Visit 1 (time 0) and 6 (168 hours)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 8, 2026

Primary Completion (Estimated)

June 1, 2027

Study Completion (Estimated)

June 1, 2027

Study Registration Dates

First Submitted

October 25, 2026

First Submitted That Met QC Criteria

November 4, 2026

First Posted (Actual)

November 12, 2026

Study Record Updates

Last Update Posted (Actual)

November 12, 2026

Last Update Submitted That Met QC Criteria

November 4, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • AP-009
  • 2025 (U.S. NIH Grant/Contract)
  • 2025-524451-31-00 (Ctis)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.